[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"doc-seo-370357-105":3,"detail-sidebar-cat-0-en-105":81,"doc-detail-370357-en":130},{"code":4,"msg":5,"data":6},0,"ok",{"site_id":7,"language":8,"slug":9,"title":10,"keywords":11,"description":12,"schema_data":13,"social_meta":74,"head_meta":76,"extra_data":78,"updated_unix":80},105,"en","integrated-analysis-of-proteome-and-transcriptome-profiling-reveals-pan-cancer-associated-pathways-and-molecular-biomarkers","Integrated Analysis of Proteome and Transcriptome Proﬁling Reveals Pan-Cancer-Associated Pathways and Molecular Biomarkers","","Integrated analysis combines mass spectrometry–based proteomic data with transcriptomic data to uncover dysregulated genes, proteins, and pathways across pan-cancer. Using proteomics from 2404 samples and transcriptomics from 7752 samples across 13 cancer types, comparisons between normal/adjacent normal tissues and tumors identify altered mRNA splicing, interferon signaling, fatty acid metabolism, and complement/coagulation pathways. Robust diagnostic biomarkers RRM2 and ADH1B are highlighted, alongside continuously dysregulated proteins across tumor stages. Prognostic risk stratification models and web tools support diagnosis, stage assessment, and risk evaluation, while drug prediction suggests inhibitors targeting CDK, HDAC, MEK, JAK, and PI3K as potential pan-cancer treatments.",{"@graph":14,"@context":73},[15,34,56],{"@type":16,"itemListElement":17},"BreadcrumbList",[18,23,27,31],{"item":19,"name":20,"@type":21,"position":22},"https://docshare.wps.com","Home","ListItem",1,{"item":24,"name":25,"@type":21,"position":26},"https://docshare.wps.com/document/","Document",2,{"item":28,"name":29,"@type":21,"position":30},"https://docshare.wps.com/document/research-report/","Research & Report",3,{"item":32,"name":10,"@type":21,"position":33},"https://docshare.wps.com/document/integrated-analysis-of-proteome-and-transcriptome-profiling-reveals-pan-cancer-associated-pathways-and-molecular-biomarkers/370357/",4,{"url":32,"name":10,"@type":35,"image":36,"author":41,"headline":10,"publisher":44,"fileFormat":47,"inLanguage":8,"description":12,"dateModified":48,"datePublished":49,"encodingFormat":47,"isAccessibleForFree":50,"interactionStatistic":51},"DigitalDocument",{"url":37,"@type":38,"width":39,"height":40},"https://docshare.wps.com/thumbnails/integrated-analysis-of-proteome-and-transcriptome-profiling-reveals-pan-cancer-associated-pathways-and-molecular-biomarkers/370357.png","ImageObject",300,407,{"name":42,"@type":43},"Miles","Person",{"url":19,"name":45,"@type":46},"DocShare","Organization","application/pdf","2026-11-18","2026-09-23",true,{"@type":52,"interactionType":53,"userInteractionCount":55},"InteractionCounter",{"@type":54},"ViewAction",9,{"@type":57,"mainEntity":58},"FAQPage",[59,65,69],{"name":60,"@type":61,"acceptedAnswer":62},"How were proteomic and transcriptomic datasets used in this pan-cancer study?","Question",{"text":63,"@type":64},"The study integrated mass spectrometry–based proteomic data (2404 samples) with transcriptomic data (7752 samples) across 13 cancer types. Tumor versus normal or adjacent-normal comparisons were used to identify dysregulated pathways, genes, and proteins.","Answer",{"name":66,"@type":61,"acceptedAnswer":67},"Which biomarkers were identified as robust pan-cancer diagnostic markers?",{"text":68,"@type":64},"RRM2 and ADH1B emerged as robust pan-cancer diagnostic biomarkers, linked to pan-cancer upregulated and downregulated gene sets.",{"name":70,"@type":61,"acceptedAnswer":71},"What models and tools were developed, and how were drugs prioritized?",{"text":72,"@type":64},"Prognostic risk stratification models were built from dysregulated genes for corresponding cancers, and web tools support diagnosis, pathologic stage assessment, and risk evaluation. Drug prediction suggested small-molecule inhibitors targeting pathways such as CDK, HDAC, MEK, JAK, and PI3K as potential pan-cancer treatments.","https://schema.org",{"og:url":32,"og:type":75,"og:title":10,"og:site_name":45,"og:description":12},"article",{"robots":77,"canonical":32},"index,follow",{"doc_id":79,"site_id":7},370357,1790352717,{"code":4,"msg":82,"data":83},"success",[84,88,92,96,101,106,111,115,119,122,126],{"id":22,"doc_module":4,"doc_module_name":25,"category_name":85,"show_sort_weight":86,"slug":87},"Story & Novel",90,"story-novel",{"id":26,"doc_module":4,"doc_module_name":25,"category_name":89,"show_sort_weight":90,"slug":91},"Literature",80,"literature",{"id":33,"doc_module":4,"doc_module_name":25,"category_name":93,"show_sort_weight":94,"slug":95},"Exam",70,"exam",{"id":97,"doc_module":4,"doc_module_name":25,"category_name":98,"show_sort_weight":99,"slug":100},5,"Comic",60,"comic",{"id":102,"doc_module":4,"doc_module_name":25,"category_name":103,"show_sort_weight":104,"slug":105},6,"Technology",50,"technology",{"id":107,"doc_module":4,"doc_module_name":25,"category_name":108,"show_sort_weight":109,"slug":110},7,"Healthcare",40,"healthcare",{"id":112,"doc_module":4,"doc_module_name":25,"category_name":29,"show_sort_weight":113,"slug":114},8,30,"research-report",{"id":55,"doc_module":4,"doc_module_name":25,"category_name":116,"show_sort_weight":117,"slug":118},"Religion & Spirituality",20,"religion-spirituality",{"id":117,"doc_module":4,"doc_module_name":25,"category_name":120,"show_sort_weight":117,"slug":121},"World Cup","world-cup",{"id":123,"doc_module":4,"doc_module_name":25,"category_name":124,"show_sort_weight":123,"slug":125},10,"Lifestyle","lifestyle",{"id":127,"doc_module":4,"doc_module_name":25,"category_name":128,"show_sort_weight":97,"slug":129},19,"General","general",{"code":4,"msg":82,"data":131},{"doc_id":79,"user_id":132,"nickname":42,"user_avatar":133,"doc_module":4,"category_id":112,"category_name":29,"doc_title":10,"doc_description":12,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":55,"is_deleted":4,"is_public":22,"is_downloadable":22,"audit_status":22,"page_count":139,"language":140,"language_code":8,"site_id":7,"html_lang":8,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":12,"update_tm":144,"read_time":145,"preview_page_count":33,"preview_urls":146},13056703019404,"https://ap-avatar.wpscdn.com/davatar_29158cc5080c5b710cf443261637dec0","Integrated Analysis of Proteome and Transcriptome Proﬁling Reveals Pan-Cancer-Associated Pathways and Molecular Biomarkers  \nAuthors  \nGuo-sheng Hu, Zao-zao Zheng, Yao-hui He, Du-chuang Wang, Rui-chao Nie, and Wen Liu  \nCorrespondence Graphical Abstract  \n[w2liu@xmu.edu.cn](w2liu@xmu.edu.cn)  \nIn Brief Proteomicand transcriptomic data across 13 cancer types were integrated to identify dysregulated pathways, such as splicing and interferon response. Pan-cancer dysregulated genes and proteins were identiﬁed to develop diagnostic, pathologic, and prognostic models, with RRM2 and ADH1B emerging as robust diagnostic biomarkers. Drug prediction suggested inhibitors targeting CDK, HDAC, and others may offer effective treatments for pan-cancer. This study highlights the power of combining proteomeand transcriptome to identify biomarkers as well as drug targets for cancer.  \nHighlights  \n• Dysregulated genes and pathways were identiﬁed in cancer or across tumor stages.  \n• Pan-cancer up-and downregulated genes (PCUG, PCDG) were identiﬁed.  \n• RRM2 and ADH1B were emerged as robust pan-cancer diagnostic biomarkers.  \n• Pan-cancer continuously up-or downregulated proteins (PCCUP, PCCDP) were detected.  \n• Cancer diagnostic, pathologic, and prognostic models were developed as web tools.  \n2025, Mol Cell Proteomics 24(3), 100919  \n© 2025 THE AUTHORS. Published by Elsevier Inc on behalf of American Society for Biochemistry and Molecular Biology. This is an open access article under the CC BY license ([http://creativecommons.org/](http://creativecommons.org/)[ ](http://creativecommons.org/)[licenses/by/4.0/](licenses/by/4.0/)).  \n[https://doi.org/10.1016/j.mcpro.2025.100919](https://doi.org/10.1016/j.mcpro.2025.100919)  \n RESEARCH  \nIntegrated Analysis of Proteome and Transcriptome Proﬁling Reveals Pan-Cancer-Associated Pathways and Molecular Biomarkers  \nGuo-sheng Hu 1 ,2 ,3 ,4 ,‡, Zao-zao Zheng2 ,3 ,4 ,‡, Yao-hui He2 ,3 ,4 ,5 ,‡, Du-chuang Wang2 ,3 ,4 ,‡,  \nRui-chao Nie2 ,3 ,4 ,6 , and Wen Liu2 ,3 ,4 ,6 ,*  \nUnderstanding dysregulated genes and pathways in cancer is critical for precision oncology. Integrating mass spectrometry–based proteomic data with transcriptomic data presents unique opportunities for systematic analyses of dysregulated genes and pathways in pan-cancer. Here, we compiled a comprehensive set of datasets, encompassing proteomic data from 2404 samples and transcriptomic data from 7752 samples across 13 cancer types. Comparisons between normal or adjacent normal tissues and tumor tissues identiﬁed several dysregulated pathways including mRNA splicing, interferon pathway, fatty acid metabolism, and complement coagulation cascade in pan-cancer. Additionally, pan-cancer upregulated and downregulated genes (PCUGs and PCDGs) were also identiﬁed. Notably, RRM2 and ADH1B, two genes which belong to PCUGs and PCDGs, respectively, were identiﬁed as robust pan-cancer diagnostic biomarkers. TNM stage-based comparisons revealed dysregulated genes and biological pathways involved in cancer progression, among which the dysregulation of complement coagulation cascade and epithelialmesenchymal transition are frequent in multiple types of cancers. A group of pan-cancer continuously upregulated and downregulated proteins in different tumor stages (PCCUPs and PCCDPs) were identiﬁed. We further constructed prognostic risk stratiﬁcation models for corresponding cancer types based on dysregulated genes, which effectively predict the prognosis for patients with these cancers. Drug prediction based on PCUGs and PCDGs as well as PCCUPs and PCCDPs revealed that small molecule inhibitors targeting CDK, HDAC, MEK, JAK, PI3K, and others might be effective treatments for pan-cancer, thereby supporting drug  \nrepurposing. We also developed web tools for cancer diagnosis, pathologic stage assessment, and risk evaluation. Overall, this study highlights the power of combining proteomic and transcriptomic data to identify valuable diagnostic and prognostic m","cbCaiunrUJTf5u5v","https://ap.wps.com/l/cbCaiunrUJTf5u5v","pdf",7450086,21,"English","# Understanding pan-cancer dysregulation\n## Multi-omics integration approach and dataset scope\n## Dysregulated pathways and gene/protein findings\n## Diagnostic biomarkers and stage-specific changes\n## Prognostic models and web tools\n## Drug prediction for pan-cancer treatments","[{\"question\":\"How were proteomic and transcriptomic datasets used in this pan-cancer study?\",\"answer\":\"The study integrated mass spectrometry–based proteomic data (2404 samples) with transcriptomic data (7752 samples) across 13 cancer types. Tumor versus normal or adjacent-normal comparisons were used to identify dysregulated pathways, genes, and proteins.\"},{\"question\":\"Which biomarkers were identified as robust pan-cancer diagnostic markers?\",\"answer\":\"RRM2 and ADH1B emerged as robust pan-cancer diagnostic biomarkers, linked to pan-cancer upregulated and downregulated gene sets.\"},{\"question\":\"What models and tools were developed, and how were drugs prioritized?\",\"answer\":\"Prognostic risk stratification models were built from dysregulated genes for corresponding cancers, and web tools support diagnosis, pathologic stage assessment, and risk evaluation. Drug prediction suggested small-molecule inhibitors targeting pathways such as CDK, HDAC, MEK, JAK, and PI3K as potential pan-cancer treatments.\"}]","Integrated Analysis of Proteome and Transcriptome Proﬁling Reveals Pan-Cancer-Associated Pathways and Molecular Biomarkers | PDF",1790188163,53,[147,151,155,159],{"page_no":22,"url":148,"width":149,"height":150},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/e5450dac4219b7c31fb51b9a7f2a7bee.webp",983,1296,{"page_no":26,"url":152,"width":153,"height":154},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/05d37fee84a27deb6f2201abce8b4818.webp",982,1294,{"page_no":30,"url":156,"width":157,"height":158},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/c499f2679bf3b491b08b37611301565f.webp",981,1293,{"page_no":33,"url":160,"width":161,"height":162},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/4e736d9064c1f8f457fe2602a3bcc8df.webp",980,1292]